ZIOPHARM Oncology Inc (ZIOP) : Traders are bullish on ZIOPHARM Oncology Inc (ZIOP) as it has outperformed the S&P 500 by a wide margin of 29.13% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.63%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.59% in the last 1 week, and is up 29.62% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
ZIOPHARM Oncology, Inc. has dropped 17.45% during the last 3-month period . Year-to-Date the stock performance stands at -29.96%. The stock has recorded a 20-day Moving Average of 13.14% and the 50-Day Moving Average is 5.72%.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): The stock opened at $5.96 on Friday but the bulls could not build on the opening and the stock topped out at $5.96 for the day. The stock traded down to $5.73 during the day, due to lack of any buying support eventually closed down at $5.82 with a loss of -2.18% for the day. The stock had closed at $5.95 on the previous day. The total traded volume was 1,137,621 shares.
Also, Equity Analysts at the Wells Fargo upgrades the rating on ZIOPHARM Oncology Inc (NASDAQ:ZIOP). The brokerage firm has issued a Market Perform rating on the shares. The shares were previously rated Underperform. The rating by the firm was issued on August 10, 2016.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).